Sinopharm mulls $4B China TCM take-private offer, Bloomberg says

China National Pharmaceutical Group, also known as Sinopharm, is mulling a renewed offer for China Traditional Chinese Medicine Holdings that could value the drugmaker at roughly $4B, Bloomberg reports, citing people with knowledge of the matter said. Sinopharm, which holds a controlling stake in China TCM, is discussing a new bid with advisers to potentially take the company private at HK$6 per share. Reference Link